Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HealiusASX:HLS 25 Price-to-Tangible-Book is 25.29 as of Sep. 11, 2026. GuruFocus rates ASX:HLS with a GF Score™ of 25/100 and a GF Value™ of A$0.96 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 151 Medical Diagnostics & Research companies, Healius ranks worse than 92.05% on this metric.
As of today (2026-09-11), Healius's share price is A$0.43. Healius's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was A$0.02. Hence, Healius's Price to Tangible Book Ratio of today is 25.29.
The historical rank and industry rank for Healius's Price-to-Tangible-Book or its related term are showing as below:
ASX:HLS'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.61 Med: 14.28 Max: 26.76
Current: 21.5
During the past 13 years, Healius's highest Price to Tangible Book Ratio was 26.76. The lowest was 5.61. And the median was 14.28.
ASX:HLS's Price-to-Tangible-Book is ranked worse than 92.05% of 151
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.56
vs ASX:HLS: 21.50
A closely related ratio is called PB Ratio. As of today, Healius's share price is A$0.43. Healius's Book Value per Sharefor the quarter that ended in Jun. 2026 was A$0.24. Hence, Healius's P/B Ratio of today is 1.82.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Healius Price-to-Tangible-Book Related Terms
Healius Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Healius's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:HLS vs TMO, DHR, NTRA: Price-to-Tangible-Book Comparison
For the Diagnostics & Research subindustry, Healius's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healius Price-to-Tangible-Book vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Healius's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Healius's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Healius (ASX:HLS) has a Price-to-Tangible-Book of 25.29 as of Sep. 11, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Healius and its competitors. According to the industry distribution chart, Healius ranks #139 out of 151 companies in the Medical Diagnostics & Research industry, placing it in the top 92.1%.
Is Healius' Price-to-Tangible-Book too high?
Healius' current Price-to-Tangible-Book is 25.29. The Medical Diagnostics & Research industry median Price-to-Tangible-Book is 2.56. Healius' value of 25.29 is 887.9% above this industry median. Based on the distribution chart, Healius ranks #139 out of 151 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Healius has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' Price-to-Tangible-Book compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Healius ranks #139 out of 151 companies for Price-to-Tangible-Book. This places Healius in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.56. Healius' value of 25.29 is 887.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Diagnostics & Research company?
The median Price-to-Tangible-Book among Medical Diagnostics & Research companies is 2.56, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healius's current Price-to-Tangible-Book of 25.29 is 887.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Healius and its competitors. For the Medical Diagnostics & Research industry, the median Price-to-Tangible-Book is 2.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healius's current Price-to-Tangible-Book is 25.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.96, compared to a current price of A$0.43 — trading 55.2% below its estimated fair value. The current Price-to-Tangible-Book is 25.29 and 887.9% above the Medical Diagnostics & Research industry median of 2.56. Healius' overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Healius (ASX:HLS), the current Price-to-Tangible-Book is 25.29 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healius (ASX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, Healius stock appears to be undervalued.
The current stock price of A$0.43 is trading 55.2% below its estimated GF Value™ of A$0.96.
GuruFocus considers Healius to be Possible Value Trap.
Key valuation signals for ASX:HLS:
Price-to-Tangible-Book: 25.29
GF Value™: A$0.96 vs. price of A$0.43 (55.2% below fair value)
Industry Position: 887.9% above the Medical Diagnostics & Research median (#139 of 151)
No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
25GF Score
Get the complete analysis for ASX:HLS
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HLS has been successfully added to your 
